139 related articles for article (PubMed ID: 15205668)
1. Amifostine and autologous hematopoietic stem cell support of escalating-dose melphalan: a phase I study.
Phillips GL; Meisenberg B; Reece DE; Adams VR; Badros A; Brunner J; Fenton R; Filicko J; Grosso D; Hale GA; Howard DS; Johnson VP; Kniska A; Marshall KW; Nath R; Reed E; Rapoport AP; Takebe N; Vesole DH; Wagner JL; Flomenberg N
Biol Blood Marrow Transplant; 2004 Jul; 10(7):473-83. PubMed ID: 15205668
[TBL] [Abstract][Full Text] [Related]
2. Activity of single-agent melphalan 220-300 mg/m2 with amifostine cytoprotection and autologous hematopoietic stem cell support in non-Hodgkin and Hodgkin lymphoma.
Phillips GL; Meisenberg BR; Reece DE; Adams VR; Badros AZ; Brunner JL; Fenton RG; Filicko J; Grosso DL; Hale GA; Howard DS; Johnson VP; Kniska A; Marshall KW; Mookerjee B; Nath R; Rapoport AP; Sarkodee-Adoo C; Takebe N; Vesole DH; Wagner JL; Flomenberg N
Bone Marrow Transplant; 2004 Apr; 33(8):781-7. PubMed ID: 14767498
[TBL] [Abstract][Full Text] [Related]
3. Phase I study for poor-prognosis lymphoma: augmentation of the "BEAM" regimen with escalating dose melphalan using amifostine cytoprotection and autologous hematopoietic stem cell transplantation--a preliminary report.
Phillips GL; Abboud CN; Bernstein SH; Friedberg JW; Ifthikharuddin JJ; Lancet JE; Liesveld JL; Spreng E; Johnson V; Chapman M; Vesole DH
Semin Oncol; 2004 Dec; 31(6 Suppl 18):59-61. PubMed ID: 15726525
[TBL] [Abstract][Full Text] [Related]
4. A phase I dose escalation study of high-dose thiotepa, melphalan and carboplatin (TMCb) followed by autologous peripheral blood stem cell transplantation (PBSCT) in patients with solid tumors and hematologic malignancies.
Demirer T; Ilhan O; Mandel NM; Arat M; Günel N; Celebi H; Ustün C; Akan H; Demirer S; Aydintuğ S; Uysal A; Koç H
Bone Marrow Transplant; 2000 Apr; 25(7):697-703. PubMed ID: 10745253
[TBL] [Abstract][Full Text] [Related]
5. A phase I trial of amifostine (WR-2721) and melphalan in children with refractory cancer.
Adamson PC; Balis FM; Belasco JE; Lange B; Berg SL; Blaney SM; Craig C; Poplack DG
Cancer Res; 1995 Sep; 55(18):4069-72. PubMed ID: 7664282
[TBL] [Abstract][Full Text] [Related]
6. A pilot study of addition of amifostine to melphalan, carboplatin, etoposide, and cyclophosphamide with autologous hematopoietic stem cell transplantation in pediatric solid tumors-A pediatric blood and marrow transplant consortium study.
Ozkaynak MF; Sahdev I; Gross TG; Levine JE; Cheerva AC; Richards MK; Rozans MK; Shaw PJ; Kadota RP
J Pediatr Hematol Oncol; 2008 Mar; 30(3):204-9. PubMed ID: 18376282
[TBL] [Abstract][Full Text] [Related]
7. High-dose topotecan, melphalan, and cyclophosphamide (TMC) with stem cell support: a new regimen for the treatment of advanced ovarian cancer.
Donato ML; Gershenson DM; Wharton JT; Ippoliti CM; Aleman AS; Bodurka-Bevers D; Bevers MW; Burke TW; Levenback CF; Wolf JK; Freedman RS; Bast RC; Gajewski JL; Champlin RE
Gynecol Oncol; 2001 Sep; 82(3):420-6. PubMed ID: 11520135
[TBL] [Abstract][Full Text] [Related]
8. A Phase I trial: dose escalation of melphalan in the "BEAM" regimen using amifostine cytoprotection.
Phillips GL; Bernstein SH; Liesveld JL; Abboud CN; Becker MW; Constine LS; Ifthikharuddin JJ; Loughner JE; Milner LA; Vesole DH; Friedberg JW
Biol Blood Marrow Transplant; 2011 Jul; 17(7):1033-42. PubMed ID: 21074630
[TBL] [Abstract][Full Text] [Related]
9. Prospective randomised trial of amifostine cytoprotection in myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantation.
Spencer A; Horvath N; Gibson J; Prince HM; Herrmann R; Bashford J; Joske D; Grigg A; McKendrick J; Prosser I; Lowenthal R; Deveridge S; Taylor K;
Bone Marrow Transplant; 2005 May; 35(10):971-7. PubMed ID: 15778725
[TBL] [Abstract][Full Text] [Related]
10. The potential of amifostine in high-dose chemotherapy and autologous hematopoietic stem cell transplantation.
Phillips GL
Semin Oncol; 2002 Dec; 29(6 Suppl 19):53-6. PubMed ID: 12577245
[TBL] [Abstract][Full Text] [Related]
11. Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: a new approaches to Neuroblastoma Therapy Consortium Study.
Matthay KK; Tan JC; Villablanca JG; Yanik GA; Veatch J; Franc B; Twomey E; Horn B; Reynolds CP; Groshen S; Seeger RC; Maris JM
J Clin Oncol; 2006 Jan; 24(3):500-6. PubMed ID: 16421427
[TBL] [Abstract][Full Text] [Related]
12. Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma.
Berenson JR; Yang HH; Sadler K; Jarutirasarn SG; Vescio RA; Mapes R; Purner M; Lee SP; Wilson J; Morrison B; Adams J; Schenkein D; Swift R
J Clin Oncol; 2006 Feb; 24(6):937-44. PubMed ID: 16418495
[TBL] [Abstract][Full Text] [Related]
13. Randomized phase 2 study of concomitant chemoradiotherapy using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancer.
Haddad R; Sonis S; Posner M; Wirth L; Costello R; Braschayko P; Allen A; Mahadevan A; Flynn J; Burke E; Li Y; Tishler RB
Cancer; 2009 Oct; 115(19):4514-23. PubMed ID: 19634161
[TBL] [Abstract][Full Text] [Related]
14. Double-conditioning regimens consisting of thiotepa, melphalan and busulfan with stem cell rescue for the treatment of pediatric solid tumors.
Hara J; Osugi Y; Ohta H; Matsuda Y; Nakanishi K; Takai K; Fujisaki H; Tokimasa S; Fukuzawa M; Okada A; Okada S
Bone Marrow Transplant; 1998 Jul; 22(1):7-12. PubMed ID: 9678789
[TBL] [Abstract][Full Text] [Related]
15. Autologous stem-cell transplantation in progressing amyloidosis is associated with severe transplant-related toxicity.
Worel N; Schulenburg A; Mitterbauer M; Keil F; Rabitsch W; Kalhs P; Gisslinger H; Raderer M; Geissler K; Höcker P; Zielinski CC; Oberbauer R; Greinix HT
Wien Klin Wochenschr; 2006 Feb; 118(1-2):49-53. PubMed ID: 16489526
[TBL] [Abstract][Full Text] [Related]
16. Amifostine reduces mucosal damage after high-dose melphalan conditioning and autologous peripheral blood progenitor cell transplantation for patients with multiple myeloma.
Thieblemont C; Dumontet C; Saad H; Roch N; Bouafia F; Arnaud P; Hequet O; Espinouse D; Salles G; Roy P; Eljaafari-Corbin A; Du Manoir-Baumgarten C; Coiffier B
Bone Marrow Transplant; 2002 Dec; 30(11):769-75. PubMed ID: 12439700
[TBL] [Abstract][Full Text] [Related]
17. Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: an update.
Bethge WA; Faul C; Bornhäuser M; Stuhler G; Beelen DW; Lang P; Stelljes M; Vogel W; Hägele M; Handgretinger R; Kanz L
Blood Cells Mol Dis; 2008; 40(1):13-9. PubMed ID: 17869547
[TBL] [Abstract][Full Text] [Related]
18. Phase I trial and pharmacokinetics of escalating doses of paclitaxel and concurrent hyperfractionated radiotherapy with or without amifostine in patients with advanced head and neck carcinoma.
Amrein PC; Clark JR; Supko JG; Fabian RL; Wang CC; Colevas AD; Posner MR; Deschler DG; Rocco JW; Finkelstein DM; McIntyre JF
Cancer; 2005 Oct; 104(7):1418-27. PubMed ID: 16116597
[TBL] [Abstract][Full Text] [Related]
19. Intravenous melphalan, thalidomide and prednisone in refractory and relapsed multiple myeloma.
Palumbo A; Avonto I; Bruno B; Ambrosini MT; Bringhen S; Cavallo F; Falco P; Boccadoro M
Eur J Haematol; 2006 Apr; 76(4):273-7. PubMed ID: 16519697
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of bortezomib and melphalan combination in patients with relapsed or refractory multiple myeloma: updated results of a phase 1/2 study after longer follow-up.
Berenson JR; Yang HH; Vescio RA; Nassir Y; Mapes R; Lee SP; Wilson J; Yellin O; Morrison B; Hilger J; Swift R
Ann Hematol; 2008 Aug; 87(8):623-31. PubMed ID: 18463870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
